Clinical trials: multiple sclerosis
Multiple Sclerosis
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An open-label extension study in which patients with multiple sclerosis received GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] for four weeks in an open-label manner.
- Trial name
- NCT01610713
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 154 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
The primary objective of this study is to evaluate whether montelukast can reduce the severity of gastrointestinal (GI) events, measured by the Gastrointestinal Symptom Rating Scale (GSRS), after oral administration of dimethyl…
- Trial name
- MITIGATE (NCT02410278)
- Testing
- dimethyl fumarate, montelukast
- Where
- 50 sites in United States
- Volunteers
- 102 people
- Sponsor
- Biogen
Multiple Sclerosis
A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis
A randomized placebo controlled double-blind cross-over trial of Dalfampridine ER for effect on ambulatory activity in people with multiple sclerosis
- Trial name
- NCT01356940
- Testing
- dalfampridine ER
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Amyotrophic Lateral Sclerosis
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease.
- Trial name
- Lithium (NCT00790582)
- Testing
- lithium carbonate
- Where
- 10 sites in United States
- Volunteers
- 109 people
- Sponsor
- Forbes Norris MDA/ALS Research Center
Multiple Sclerosis
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease associated with central nervous system (CNS) demyelination and subsequent axonal degeneration. Multiple sclerosis exhibits an unpredictable and variable clinical course.
- Trial name
- NCT01517282
- Testing
- MOR103
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 32 people
- Sponsor
- MorphoSys AG
Multiple Sclerosis
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
- Trial name
- NCT02576717
- Testing
- RPC1063
- Where
- 175 sites in United States, Belarus and 24 more
- Volunteers
- 2,494 people
- Sponsor
- Celgene
Multiple Sclerosis
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate
The purpose of this study is to assess the effect of Diclofenac Sodium Topical Gel (DSTG) on injection site reaction following self-administer glatiramer acetate in people with Multiple Sclerosis.
- Trial name
- NCT01454791
- Testing
- diclofenac sodium topical gel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Depression, Relapsing-remitting Multiple Sclerosis
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
This is a prospective, multi-center, open-label study in Relapsing-remitting Multiple Sclerosis (RRMS) patients with mild to moderate depression treated with selected serotonin reuptake inhibitors (SSRI) or serotonin and…
- Trial name
- REGAIN (NCT01436643)
- Testing
- Venlafaxine, Fluoxetine, Citalopram
- Where
- 25 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
This study is an open-label, non-randomized study to evaluate rate and severity of infusion-related reactions (IRRs) of ocrelizumab infused over a shorter time period than the approved administration rate in participants with…
- Trial name
- NCT03606460
- Testing
- Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3
- Where
- 5 sites in United States
- Volunteers
- 141 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS
Multiple sclerosis (MS) is the leading cause of irreversible neurological disability among young women and the second leading cause of disability among young men in the U.S.
- Trial name
- ABC's of MS (NCT03808545)
- Testing
- Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS), BIPAMS + Diet
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Alabama at Birmingham
Multiple Sclerosis
Integrating Caregiver Support Into MS Care
With loss of mobility in multiple sclerosis (MS) comes an increase in amount and types of caregiver assistance, with a concomitant increase in burden for the caregiver.
- Trial name
- NCT02835677
- Testing
- Behavioral
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Examining a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis
The goal of this randomized controlled clinical trial is to examine the feasibility and initial efficacy of undertaking and delivering a novel, stakeholder-informed exercise training program for wheelchair users with multiple…
- Trial name
- NCT05888727
- Testing
- Seated Physical activity INtervention for persons with MS, "SPIN" program- Intervention Condition, WEllness for Longevity Living with MS (WELL)- Control Condition
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Sclerosis, Fatigue
Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue
This prospective case series will use mixed methods to examine the feasibility, acceptability, and initial effects of three telehealth cognitive behavioral therapy components (relaxation training, behavioral activation, cognitive…
- Trial name
- NCT05848323
- Testing
- 4-week Relaxation Training, 4-week Behavioral Activation, 4-week Cognitive Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Multiple Sclerosis
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
This study will test the tolerability and preliminary efficacy of transcranial direct current stimulation (tDCS) combined with a cognitive training program, remotely-delivered using a telemedicine protocol in 60 adults with…
- Trial name
- NCT02746705
- Testing
- Transcranial Direct Current Stimulation (tDCS), Cognitive Training Program
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Multiple Sclerosis, Relapsing-Remitting
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
- Trial name
- PRIVIG (NCT00220779)
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 128 people
- Sponsor
- Grifols Therapeutics LLC
Multiple Sclerosis, Relapsing-Remitting
Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells
Open-label, single center, phase I clinical trial to assess the safety, tolerability and preliminary efficacy and in vivo mechanisms of action of i.v.
- Trial name
- ETIMS (NCT01414634)
- Testing
- ETIMS
- Volunteers
- 9 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Tuberous Sclerosis Complex
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy.
- Trial name
- NCT05323734
- Testing
- Ganaxolone
- Where
- 63 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Marinus Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting…
- Trial name
- EXPLORE (NCT01156311)
- Testing
- dimethyl fumarate
- Where
- 16 sites in United States
- Volunteers
- 108 people
- Sponsor
- Biogen
Multiple Sclerosis
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of…
- Trial name
- CONCERTO (NCT01707992)
- Testing
- Laquinimod
- Where
- 284 sites in United States, Austria and 28 more
- Volunteers
- 2,199 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Urinary Bladder Diseases
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
This study will assess the impact of a systematic bladder health screening and disease education regimen as well as the implementation of a referral process on the quality of life of multiple sclerosis patients with bladder…
- Trial name
- NCT01930799
- Testing
- Systematic Screening and Education Regimen
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Allergan